A phase I trial of the Hedgehog inhibitor, sonidegib (LDE225), in combination with etoposide and cisplatin for the initial treatment of extensive stage small cell lung cancer

OBJECTIVES: The Hedgehog pathway has been implicated in small cell lung cancer (SCLC) tumor initiation and progression. Pharmacologic blockade of the key Hedgehog regulator, Smoothened, may inhibit these processes. We performed a phase I study to determine the maximum tolerated dose (MTD) of sonideg...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Lung Cancer
Päätekijät: Pietanza, M. Catherine, Litvak, Anya M., Varghese, Anna M., Krug, Lee M., Fleisher, Martin, Teitcher, Jerrold B., Holodny, Andrei I., Sima, Cami S., Woo, Kaitlin M., Ng, Kenneth K., Won, Helen H., Berger, Michael F., Kris, Mark G., Rudin, Charles M.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2016
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5427482/
https://ncbi.nlm.nih.gov/pubmed/27565909
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.lungcan.2016.04.014
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia